Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NG9 | ISIN: US83548R4020 | Ticker-Symbol: H3D0
NASDAQ
23.01.25
22:00 Uhr
1,710 US-Dollar
-0,290
-14,50 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSonnet BioTherapeutics Holdings, Inc. - S-1, General form for registration of securities1
MiSonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar3
DiSonnet BioTherapeutics startet Studie mit Kombination aus SON-1010 und Trabectedin3
DiSonnet BioTherapeutics begins trial combining SON-1010, trabectedin1
DiSonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas95SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with...
► Artikel lesen
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
DiSonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
23.12.24Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment2
17.12.24Insights into Sonnet BioTherapeutics Q4 Earnings2
17.12.24Sonnet BioTherapeutics GAAP EPS of -$11.352
17.12.24Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update92Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase...
► Artikel lesen
17.12.24Sonnet BioTherapeutics Holdings, Inc. - 10-K, Annual Report-
17.12.24Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
09.12.24Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules5
09.12.24Sonnet BioTherapeutics reports progress in cancer trial3
09.12.24Sonnet BioTherapeutics verzeichnet Fortschritte in Krebsstudie11
09.12.24Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial159The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation...
► Artikel lesen
04.12.24Sonnet BioTherapeutics meldet Fortschritte bei Krebsbehandlungsmedikament14
04.12.24Sonnet BioTherapeutics reports advances in cancer treatment drug5
04.12.24Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action2
04.12.24Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
Seite:  Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1